Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Añadir filtros








Intervalo de año
1.
Asian Journal of Andrology ; (6): 24-29, 2018.
Artículo en Inglés | WPRIM | ID: wpr-1009523

RESUMEN

Emerging evidence indicates that aldosterone and mineralocorticoid receptors (MRs) are associated with the pathogenesis of erectile dysfunction. However, the molecular mechanisms remain largely unknown. In this study, freshly isolated penile corpus cavernosum tissue from rats was treated with aldosterone, with or without MRs inhibitors. Nuclear factor (NF)-kappa B (NF-κB) activity was evaluated by real-time quantitative PCR, luciferase assay, and immunoblot. The results demonstrated that mRNA levels of the NF-κB target genes, including inhibitor of NF-κB alpha (IκB-α), NF-κB1, tumor necrosis factor-alpha (TNF-α), and interleukin 6 (IL-6), were higher after aldosterone treatment. Accordingly, phosphorylation of p65/RelA, IκB-α, and inhibitor of NF-κB kinase-β was markedly increased by aldosterone. Furthermore, knockdown of MRs prevented activation of the NF-κB canonical pathway by aldosterone. Consistent with this finding, ectopic overexpression of MRs enhanced the transcriptional activation of NF-κB by aldosterone. More importantly, the MRs antagonist, spironolactone blocked aldosterone-mediated activation of the canonical NF-κB pathway. In conclusion, aldosterone has an inflammatory effect in the corpus cavernosum penis, inducing NF-κB activation via an MRs-dependent pathway, which may be prevented by selective MRs antagonists. These data reveal the possible role of aldosterone in erectile dysfunction as well as its potential as a novel pharmacologic target for treatment.


Asunto(s)
Animales , Masculino , Ratas , Aldosterona/farmacología , Citocinas/biosíntesis , Técnicas de Silenciamiento del Gen , Quinasa I-kappa B/antagonistas & inhibidores , Interleucina-6/genética , Antagonistas de Receptores de Mineralocorticoides/farmacología , FN-kappa B/genética , Pene/metabolismo , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , ARN Mensajero/biosíntesis , Ratas Endogámicas WKY , Receptores de Mineralocorticoides/genética , Transducción de Señal/efectos de los fármacos , Espironolactona/farmacología , Activación Transcripcional , Factor de Necrosis Tumoral alfa/biosíntesis , Quinasa de Factor Nuclear kappa B
2.
Acta cir. bras ; 29(11): 696-702, 11/2014. tab, graf
Artículo en Inglés | LILACS | ID: lil-728643

RESUMEN

PURPOSE: To explore the mechanism of resistance to IKKβ inhibitor in multiple myeloma (MM) cells and uncover novel therapeutic targets for MM. METHODS: We downloaded the microarray data (GSE8476) from GEO (Gene Expression Omnibus) database. The data were derived from the human MM cells lines (L363 cells) treated with IKKβ inhibitor MLN120b (MLN) for eight, 12 and 24 hours. Furthermore, we applied the Search Tool for the Retrieval of Interacting Genes (STRING) and Expression Analysis Systematic Explorer (EASE) database to construct protein-protein interaction networks and identified over-represented pathway among DEGs (differentially expressed genes). RESULTS: We obtained 108 DGEs in 8h vs. 12h group and 101 ones in 8h vs. 24h group. Most of DGEs were found to be involved in biological regulation. The significant pathways were Ig A pathway and the CAMs pathways. In addition, 24 common DGEs were found in the networks of the two groups such as ICAM 3 and SELL. CONCLUSION: Intercellular adhesion molecule 3 and SELL may be potential targets in multiple myeloma treatment in the future. .


Asunto(s)
Humanos , Marcación de Gen/métodos , Quinasa I-kappa B/antagonistas & inhibidores , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/genética , Análisis de Secuencia por Matrices de Oligonucleótidos/métodos , Adhesión Celular , Línea Celular Tumoral , Análisis por Conglomerados , Quinasa I-kappa B/metabolismo , Mieloma Múltiple/metabolismo , Reproducibilidad de los Resultados , Factores de Tiempo
3.
Experimental & Molecular Medicine ; : 513-520, 2012.
Artículo en Inglés | WPRIM | ID: wpr-192551

RESUMEN

During ischemia-reperfusion injury, brief pre-exposure to oxidative stress renders organs resistant to subsequent severe damage. NF-kappaB is a transcription factor that is involved in reperfusion-induced inflammatory and immune responses. The activity of NF-kappaB has been shown to be modulated by oxidative stress in various cell types through different pathways. We studied the effect of pre-exposure to oxidative stress on subsequent NF-kappaB activation in TNFalpha-stimulated HEK293 cells. The cells were transiently exposed to 0.5 mM H2O2 for 20 min, prior to stimulation with TNFalpha, and the subsequent expression of NF-kappaB-dependent genes and the levels of NF-kappaB signaling molecules were measured. Pre-exposure to H2O2 significantly delayed the TNFalpha-induced expression of an NF-kappaB reporter gene and inflammatory proteins (intercellular adhesion molecule-1 and IL-1beta). The degradation of inhibitor of NF-kappaB alpha (IkappaBalpha) and the nuclear translocation of NF-kappaB were also delayed by H2O2 treatment, whereas IkappaBalpha phosphorylation and IkappaB kinase activity were not changed. When we examined the ubiquitin/proteosome pathway in H2O2-treated cells, we could not detect significant changes in proteosomal peptidase activities, but we were able to detect a delay of IkappaBalpha poly-ubiquitination. Our results suggest that transient exposure to oxidative stress temporally inhibits NF-kappaB-dependent gene expression by suppressing the poly-ubiquitination of phosphorylated IkappaBalpha in HEK293 cells.


Asunto(s)
Humanos , Transporte Activo de Núcleo Celular , Núcleo Celular/metabolismo , Activación Enzimática/efectos de los fármacos , Células HEK293 , Peróxido de Hidrógeno/farmacología , Quinasa I-kappa B/antagonistas & inhibidores , Fosforilación/efectos de los fármacos , Transporte de Proteínas , Factor de Necrosis Tumoral alfa/farmacología , Ubiquitinación/efectos de los fármacos
4.
Experimental & Molecular Medicine ; : 277-287, 2009.
Artículo en Inglés | WPRIM | ID: wpr-49339

RESUMEN

Matrix metalloproteinase-9 (MMP-9) may play an important role in emphysematous change in chronic obstructive pulmonary disease (COPD), one of the leading causes of mortality and morbidity worldwide. We previously reported that simvastatin, an inhibitor of HMG-CoA reductase, attenuates emphysematous change and MMP-9 induction in the lungs of rats exposed to cigarette smoke. However, it remained uncertain how cigarette smoke induced MMP-9 and how simvastatin inhibited cigarette smoke-induced MMP-9 expression in alveolar macrophages (AMs), a major source of MMP-9 in the lungs of COPD patients. Presently, we examined the related signaling for MMP-9 induction and the inhibitory mechanism of simvastatin on MMP-9 induction in AMs exposed to cigarette smoke extract (CSE). In isolated rat AMs, CSE induced MMP-9 expression and phosphorylation of ERK and Akt. A chemical inhibitor of MEK1/2 or PI3K reduced phosphorylation of ERK or Akt, respectively, and also inhibited CSE-mediated MMP-9 induction. Simvastatin reduced CSE-mediated MMP-9 induction, and simvastatin-mediated inhibition was reversed by farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP). Similar to simvastatin, inhibition of FPP transferase or GGPP transferase suppressed CSE-mediated MMP-9 induction. Simvastatin attenuated CSE-mediated activation of RAS and phosphorylation of ERK, Akt, p65, IkappaB, and nuclear AP-1 or NF-kappaB activity. Taken together, these results suggest that simvastatin may inhibit CSE-mediated MMP-9 induction, primarily by blocking prenylation of RAS in the signaling pathways, in which Raf-MEK-ERK, PI3K/Akt, AP-1, and IkappaB-NF-kappaB are involved.


Asunto(s)
Animales , Ratas , Fosfatidilinositol 3-Quinasa/metabolismo , Transferasas Alquil y Aril/metabolismo , Anticolesterolemiantes/farmacología , Células Cultivadas , Inhibidores Enzimáticos/metabolismo , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Quinasa I-kappa B/antagonistas & inhibidores , Macrófagos Alveolares/citología , Metaloproteinasa 9 de la Matriz/genética , Quinasas de Proteína Quinasa Activadas por Mitógenos/metabolismo , Fosfatos de Poliisoprenilo/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Sesquiterpenos/metabolismo , Transducción de Señal/fisiología , Simvastatina/farmacología , Humo/efectos adversos , Nicotiana/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA